All articles by Shreosree Banerjee

US FDA grants priority review to Eisai’s new drug application for anticancer drug lenvatinib

The US Food and Drug Administration (FDA) has granted priority review status to the supplemental new drug application (sNDA) submitted by Eisai for its anticancer agent lenvatinib mesylate, as a treatment for patients with kidney cancer.